Sandbox vidit: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 62: | Line 62: | ||
<tr><td>Quinidine</td><td>600 to 1500 mg</td></tr> | <tr><td>Quinidine</td><td>600 to 1500 mg</td></tr> | ||
<tr><td>Sotalol</td> <td>160 to 320 mg </td></tr> | <tr><td>Sotalol</td> <td>160 to 320 mg </td></tr> | ||
</table> | |||
===Pharmacological Agents for Heart Rate Control=== | |||
<table class="wikitable"> | |||
<tr class="v-firstrow"><th>Drug</th><th>Class/LOE <br> Recommendations</th><th>Loading Dose</th><th>Maintenance Dose</th></tr> | |||
<tr><th>Acute Setting</th></tr> | |||
<tr><th>Heart rate control in patients without accessory pathway</th></tr> | |||
<tr><td>Esmolol</td><td>I C</td><td>500 mcg/kg IV over 1 min</td><td>60 to 200 mcg/kg/min IV</td></tr> | |||
<tr><td>Propanolol</td><td>I C </td><td>0.15 mg/kg IV</td><td>NA</td></tr> | |||
<tr><td>Metoprolol</td><td>I C </td><td>2.5 to 5 mg IV bolus over 2 min; up to 3 doses</td><td>NA</td></tr> | |||
<tr><td>Diltiazem</td><td>I B</td><td>0.25 mg/kg IV over 2 min</td><td>5 to 15 mg/h IV</td></tr> | |||
<tr><td>Verampil</td><td>I B</td><td>0.075 to 0.15 mg/kg IV over 2 min</td><td>NA</td></tr> | |||
<tr><th>Heart Rate Control in patients with accessory pathway</th></tr> | |||
<tr><td>Amiodarone</td><td>IIa C</td><td>150 mg over 10 min</td><td>0.5 to 1 mg/min IV</td></tr> | |||
<tr><th>Heart Rate Control in patients with heart failure and without accessory pathway</th></tr> | |||
<tr><td>Digoxin</td><td>I B</td><td>0.25 mg IV each 2 h, up to 1.5 mg</td><td>0.125 to 0.375 mg daily IV or orally</td></tr> | |||
<tr><td>Amiodarone</td><td>IIa C</td><td>150 mg over 10 min</td><td>0.5 to 1 mg/min IV</td></tr> | |||
<tr><td></td><td></td><td></td><td></td></tr> | |||
<tr><td></td><td></td><td></td><td></td></tr> | |||
<tr><td></td><td></td><td></td><td></td></tr> | |||
<tr><td></td><td></td><td></td><td></td></tr> | |||
<tr><td></td><td></td><td></td><td></td></tr> | |||
<tr><td></td><td></td><td></td><td></td></tr> | |||
</table> | </table> |
Revision as of 17:12, 3 March 2014
Cardioversion upto7 Days
Drug | Class of Recommendation/ Level of Evidence | Dosage | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Agents with proven efficacy | ||||||||||||
Dofetilide | I A |
| ||||||||||
Flecainide | I A | Oral: 200 to 300 mg Intravenous: 1.5 to 3.0 mg/kg over 10 to 20 min | ||||||||||
Ibutilide | I A | 1 mg over 10 min; repeat 1 mg when necessary | ||||||||||
Propafenone | I A | Oral: 600 mg Intravenous: 1.5 to 2.0 mg/kg over 10 to 20 min | ||||||||||
Amiodarone | IIa A | Oral:
Intravenous:
|
Cardioversion after 7 Days
Drug | Class of Recommendation/ Level of Evidence | Dosage | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Dofetilide | I A |
| ||||||||||
Amiodarone | IIa A | Oral:
Intravenous:
| ||||||||||
Ibutilide | IIa A | 1 mg over 10 min; repeat 1 mg when necessary |
Drugs which enhance the efficacy of cardioversion when given prior to the procedure: (Level of recommendation: IIa B)
- Amiodarone
- Flecainide
- Ibutilide
- Propafenone
- Sotalol
Drug Dosages for Maintenance of Sinus Rhythm
Following table summarizes the list of most commonly used drugs and their dosages for maintenance of sinus rhythm:
Drug | Dose |
---|---|
Amiodarone | 100 to 400 mg |
Disopyramide | 400 to 750 mg |
Dofetilide | 5000 to 1000 mcg |
Flecainide | 200 to 300 mg |
Procainamide | 1000 to 4000 mg |
Propafenone | 450 to 900 mg |
Quinidine | 600 to 1500 mg |
Sotalol | 160 to 320 mg |
Pharmacological Agents for Heart Rate Control
Drug | Class/LOE Recommendations | Loading Dose | Maintenance Dose |
---|---|---|---|
Acute Setting | |||
Heart rate control in patients without accessory pathway | |||
Esmolol | I C | 500 mcg/kg IV over 1 min | 60 to 200 mcg/kg/min IV |
Propanolol | I C | 0.15 mg/kg IV | NA |
Metoprolol | I C | 2.5 to 5 mg IV bolus over 2 min; up to 3 doses | NA |
Diltiazem | I B | 0.25 mg/kg IV over 2 min | 5 to 15 mg/h IV |
Verampil | I B | 0.075 to 0.15 mg/kg IV over 2 min | NA |
Heart Rate Control in patients with accessory pathway | |||
Amiodarone | IIa C | 150 mg over 10 min | 0.5 to 1 mg/min IV |
Heart Rate Control in patients with heart failure and without accessory pathway | |||
Digoxin | I B | 0.25 mg IV each 2 h, up to 1.5 mg | 0.125 to 0.375 mg daily IV or orally |
Amiodarone | IIa C | 150 mg over 10 min | 0.5 to 1 mg/min IV |